We are live on
!
Find out more
PA
PharVision Advisers Portfolio holdings
AUM
$9.86M
1-Year Est. Return
9.93%
This Fund
S&P 500
This Quarter
Est. Return
+0.93%
1 Year Est. Return
+9.93%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$198M
AUM Growth
+$19.8M
(+11%)
Cap. Flow
+$23.3M
Cap. Flow
% of AUM
11.78%
Top 10 Holdings %
Top 10 Hldgs %
3.45%
Holding
1,063
New
409
Increased
141
Reduced
117
Closed
396
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Delek US
DK
|
+$871K |
| 2 |
Broadcom
AVGO
|
+$691K |
| 3 |
Agilent Technologies
A
|
+$650K |
| 4 |
Telos
TLS
|
+$640K |
| 5 |
Pagaya Technologies
PGY
|
+$627K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Array Technologies
ARRY
|
+$730K |
| 2 |
Vertiv
VRT
|
+$639K |
| 3 |
Zevra Therapeutics
ZVRA
|
+$635K |
| 4 |
BOW
Bowhead Specialty Holdings
BOW
|
+$608K |
| 5 |
Rigel Pharmaceuticals
RIGL
|
+$581K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.19% |
| 2 | Industrials | 15.13% |
| 3 | Financials | 12.4% |
| 4 | Consumer Discretionary | 11.79% |
| 5 | Healthcare | 11.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
901
NewMarket
NEU
$7.27B
| – | – |
-248
| Closed | -$205K |
|
902
National Grid
NGG
$81.9B
| – | – |
-3,895
| Closed | -$279K |
|
903
Nike
NKE
$64B
| – | – |
-4,662
| Closed | -$325K |
|
904
Nano X Imaging
NNOX
$61.6M
| – | – |
-15,194
| Closed | -$56.2K |
|
905
Nomad Foods
NOMD
$1.72B
| – | – |
-15,240
| Closed | -$200K |
|
906
Nutrien
NTR
$33.2B
| – | – |
-6,345
| Closed | -$373K |
|
907
Nu Holdings
NU
$71.4B
| – | – |
-10,234
| Closed | -$164K |
|
908
Envista
NVST
$4.37B
| – | – |
-15,070
| Closed | -$307K |
|
909
NexGen Energy
NXE
$6.1B
| – | – |
-41,870
| Closed | -$375K |
|
910
Nextpower Inc
NXT
$14.8B
| – | – |
-4,538
| Closed | -$336K |
|
911
New York Times
NYT
$12.1B
| – | – |
-6,294
| Closed | -$361K |
|
|
OBE
912
Obsidian Energy
OBE
$634M
| – | – |
-28,630
| Closed | -$187K |
|
913
OFG Bancorp
OFG
$2.24B
| – | – |
-4,887
| Closed | -$213K |
|
914
Omnicom Group
OMC
$24.7B
| – | – |
-5,232
| Closed | -$427K |
|
915
Option Care Health
OPCH
$3.52B
| – | – |
-9,761
| Closed | -$271K |
|
916
OppFi
OPFI
$828M
| – | – |
-19,140
| Closed | -$217K |
|
917
Oportun Financial
OPRT
$267M
| – | – |
-12,489
| Closed | -$77.1K |
|
918
Oscar Health
OSCR
$9.09B
| – | – |
-11,282
| Closed | -$214K |
|
919
Oshkosh
OSK
$9.5B
| – | – |
-1,930
| Closed | -$250K |
|
920
Oxford Industries
OXM
$630M
| – | – |
-5,331
| Closed | -$216K |
|
921
Bank OZK
OZK
$5.57B
| – | – |
-9,486
| Closed | -$484K |
|
922
PagSeguro Digital
PAGS
$2.66B
| – | – |
-10,269
| Closed | -$103K |
|
923
Par Pacific Holdings
PARR
$3.95B
| – | – |
-13,279
| Closed | -$470K |
|
924
Paycom
PAYC
$7.55B
| – | – |
-1,573
| Closed | -$327K |
|
925
Payoneer
PAYO
$2.41B
| – | – |
-54,830
| Closed | -$332K |
|
Similar funds
BS
RG
MP
CCM
DFA
CCP
FRT
VH
PharVision Advisers's Q4 2025 Portfolio in Review
As of Q4 2025, PharVision Advisers held 1,063 positions worth $198M, up 11% from $178M the previous quarter. Its ten largest holdings account for 3.5% of the portfolio.
PharVision Advisers deployed $23.3M of net new capital in Q4 2025, opening 409 new positions and adding to 141 existing holdings. Its largest new stake was Delek US: 24,407 shares worth $724K.
By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 15% a quarter earlier, followed by Industrials and Financials.
On the sell side, the largest reduction was Wayfair, an estimated $510K trimmed.
- PharVision Advisers's largest Q4 2025 buy was Delek US: 24,407 shares worth $724K.
- PharVision Advisers added most to NIO in Q4 2025, an estimated $557K increase.
- PharVision Advisers's biggest Q4 2025 reduction was Wayfair, cutting an estimated $510K.
- PharVision Advisers fully exited Array Technologies in Q4 2025, selling an estimated $730K.
- PharVision Advisers's ten largest holdings make up 3.5% of its $198M portfolio in Q4 2025.
- PharVision Advisers opened 409 new positions and closed 396 in Q4 2025.
- PharVision Advisers's portfolio value rose 11% quarter-over-quarter to $198M.
Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.